Clinical trials: Depression Anxiety Disorder
Psychological Stress, Sleep Disturbance
Sleep More, Stress Less: 90-Day Trial of Neuralli Mood
This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in…
- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms
- Trial name
- NM90 (NCT07717385)
- Testing
- Neuralli Mood
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Anxiety, Fear
An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus
A high-quality broad-spectrum cannabidiol supplement with a bio-terpene complex will be administered once daily. It is hypothesized that this supplement will lead to improvements in sleep, focus, and stress.
- Conditions
- Anxiety, Fear, Stress, Low Mood
- Trial name
- NCT05518019
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prima CBD
Depression, Anxiety
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or…
- Trial name
- NCT02878928
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- 17 sites in United States
- Volunteers
- 579 people
- Sponsor
- AltheaDx
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Depressive Disorder and Anxiety Disorders
First Study in Humans With GSK424887
This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body…
- Trial name
- NCT01059591
- Testing
- GSK424887, PET
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sleep Disorder (Disorder), Anxiety Depression Disorder
The Effect of Avnace eZZe on Sleep Improvement
This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe…
- Trial name
- NCT07172607
- Testing
- Avance eZZe drink, Avance eZZe drink (without liposomal)
- Where
- Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Healthy Subjects, Depressive Disorder and Anxiety Disorders
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00435695
- Testing
- GSK163090
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Depression, Anxiety
Evaluating Neuromodulation Technologies in Early Recovery
The study is an open-label comparative effectiveness clinical trial evaluating the impact of three neuromodulation treatment devices to improve the mental health and sobriety status of recovering substance abuse patients.
- Conditions
- Depression, Anxiety, Insomnia
- Trial name
- NCT01993277
- Testing
- Nexalin Brain Stimulator, Fischer Wallace Stimulator, David Delight Stimulator
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Behavioral Health of the Palm Beaches
Depression, Anxiety
Meru Health Program for Cancer Patients With Depression and Anxiety
The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP).
- Trial name
- NCT05588622
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Meru Health, Inc.
Anxiety, Depression
Ginger.io Behavioral Health Study
This Study will evaluate the impact of a smartphone-based platform on a range of outcomes for medically-underserved patients with mood disorders (e.g.
- Conditions
- Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT02491307
- Testing
- Ginger.io Smartphone Application
- Where
- 4 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Emotional Dysregulation, Therapeutic Alliance
Effectiveness of the SoundHeal Multi-Sensory Integrative Therapy Among Justice-Involved Youth
Emotional dysregulation in justice-involved youth (JIY) is a condition that significantly impacts young people, their families, and juvenile justice and public health systems.
- Conditions
- Emotional Dysregulation, Therapeutic Alliance, Depression Disorder, Anxiety Disorders
- Trial name
- HEAL-SLOJSC (NCT07364799)
- Testing
- Multi-sensory emotional regulation intervention (Heal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- SoundHeal
Social Phobia
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
- Trial name
- NCT00555139
- Testing
- GSK561679 tablet, GW876008 tablet, alprazolam
- Where
- 8 sites in Spain
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Healthy Volunteers
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
This Phase I/II clinical trial investigates the safety, tolerability, and potential therapeutic benefits of a novel sublingual formulation of 5-MeO-DMT.
- Trial name
- 5-MeO-DMT (NCT06816667)
- Testing
- BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Mental Health Issue, Mental Health Disorder
Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions
US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of two arms.
- Conditions
- Mental Health Issue, Mental Health Disorder, Mental Health, Depression
- Trial name
- NCT06190184
- Testing
- VIOME Precision Nutrition Program, Control arm
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Viome
Opioid-use Disorder, Depression, Anxiety
Transcranial Photobiomodulation for the Treatment of Opioid Cravings
The investigators wish to test the hypothesis that transcranial photobiomodulation (tPBM) (i.e., 4-minutes of 810nm near-infrared light at 250 mW/cm2 by LED to the forehead at F3 or F4 versus an indistinguishable placebo…
- Conditions
- Opioid-use Disorder, Depression, Anxiety, Craving
- Trial name
- NCT04417738
- Testing
- unilateral transcranial photobiomodulation, near infrared mode
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MindLight, LLC
Depression, Anxiety Disorders
Prospective Study of the Evaluation of Disease contRol and the Quality of Life of Patients With depressiOn and With or Without aNxiety disOrders in the Greek populatIon
Depression is a psychiatric disorder that affects mood, thoughts and is usually accompanied by physical annoyances. It affects the person's eating habits, his sleep, the way he sees himself and the way he thinks and understands.
- Trial name
- PRONOI (NCT03317262)
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.